Find clinical trials for Chronic Lymphocytic Leukemia in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Paris, Île-de-France, FRA:
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Bobigny Cedex, France and 40 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Bobigny, France and 130 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Paris, Cedex 13, France and 179 other locations
study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...
Phase 1, Phase 2
Paris, France and 74 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Villejuif, France and 85 other locations
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...
Phase 1, Phase 2
Villejuif, France and 49 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
Bobigny, Cedex, France and 231 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Paris cedex 10, Paris, France and 196 other locations
Ibrutinib, a first-in-class Bruton Tyrosine kinase (BTK) inhibitor, has become an established treatment in relapsed/refractory chronic lymphocytic...
Phase 2
Paris, France and 23 other locations
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or...
Phase 3
Creteil, France and 47 other locations
Clinical trials
Research sites
Resources
Legal